Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.01 Insider Own5.10% Shs Outstand72.57M Perf Week-0.92%
Market Cap9.07B Forward P/E- EPS next Y-4.04 Insider Trans0.30% Shs Float70.62M Perf Month-17.60%
Income-570.30M PEG- EPS next Q-1.33 Inst Own96.50% Short Float17.76% Perf Quarter2.70%
Sales344.60M P/S26.31 EPS this Y-533.90% Inst Trans1.08% Short Ratio10.29 Perf Half Y-9.75%
Book/sh14.86 P/B8.41 EPS next Y44.80% ROA-34.90% Target Price209.67 Perf Year-0.61%
Cash/sh15.20 P/C8.22 EPS next 5Y-0.20% ROE-55.40% 52W Range95.21 - 165.87 Perf YTD14.50%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-23.60% 52W High-24.67% Beta2.12
Dividend %- Quick Ratio7.80 Sales past 5Y84.10% Gross Margin85.50% 52W Low31.24% ATR6.17
Employees499 Current Ratio8.80 Sales Q/Q28.80% Oper. Margin- RSI (14)33.93 Volatility4.13% 4.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-124.00% Profit Margin- Rel Volume1.00 Prev Close121.97
ShortableYes LT Debt/Eq0.39 EarningsAug 07 AMC Payout- Avg Volume1.22M Price124.95
Recom1.70 SMA20-11.08% SMA50-10.20% SMA200-1.99% Volume1,223,583 Change2.44%
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Jan-22-18Initiated RBC Capital Mkts Outperform
Aug-18-19 05:59PM  Weekly CEO Buys Highlight
Aug-17-19 01:46PM  The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week Benzinga
Aug-16-19 06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Aug-14-19 02:12PM  Edited Transcript of SRPT earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
05:30AM  Xontogeny, accelerator launched by former Sarepta CEO, preps five new biotechs American City Business Journals
Aug-12-19 07:15PM  Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares
Aug-09-19 12:24PM  Why Sarepta Therapeutics Stock Tanked on Thursday Motley Fool -5.17%
05:58AM  Sarepta Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-08-19 04:35PM  Why Zillow Group, Sarepta Therapeutics, and CenturyLink Slumped Today Motley Fool -6.52%
04:26PM  Sarepta stock tumbles after Duchenne gene therapy complication American City Business Journals
04:08PM  This Biotech Crashed On 'Erroneous' Report Plus 2 Stocks That Diverged Investor's Business Daily
03:49PM  Sarepta stock drops on erroneous adverse event report to FDA MarketWatch
03:27PM  Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS) GlobeNewswire
12:56PM  UPDATE 1-Patient in Sarepta gene therapy trial develops serious illness; shares plunge Reuters
12:44PM  Sarepta says adverse event report for DMD gene therapy erroneously submitted Reuters
10:33AM  Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval Zacks
09:24AM  Sarepta Therapeutics (SRPT) Q2 2019 Earnings Call Transcript Motley Fool
06:00AM  What You'll Want to Know About Sarepta Therapeutics' Q2 Results Motley Fool
Aug-07-19 07:54PM  Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy American City Business Journals
06:25PM  Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
08:24AM  A Preview Of Sarepta Therapeutics Q2 Earnings Benzinga
Jul-31-19 06:04PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
04:30PM  Sarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019 GlobeNewswire
Jul-29-19 09:08AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Jul-24-19 02:22PM  ICER, advocates prep for tense meeting on Sarepta's Duchenne drugs American City Business Journals
08:36AM  Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Financial Strength Analysis Simply Wall St.
Jul-18-19 09:30AM  Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-17-19 03:22PM  The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On Motley Fool
07:43AM  Sarepta vs Pfizer: Which Stock Should Investors Buy? TipRanks
Jul-12-19 08:57AM  Sarepta Therapeutics Looks Ready to Break Out to the Upside
Jul-08-19 09:55AM  Sarepta Stock Up Almost 40% This Year So Far: Here's Why Zacks
Jul-01-19 10:11AM  Sarepta Therapeutics Stock Could Capitalize From Pfizers Stumble
09:35AM  Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues Zacks
09:21AM  Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study Zacks
09:15AM  Stocks Soar 7% in June Zacks
Jun-28-19 04:30PM  Why CalAmp, Sarepta Therapeutics, and Motorcar Parts of America Jumped Today Motley Fool +17.10%
04:28PM  Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying Investor's Business Daily
04:27PM  Here's Why Sarepta Therapeutics Is Surging Today Motley Fool
01:35PM  Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems
12:28PM  Street Crowns Sarepta DMD Gene Therapy King After Pfizer Results Bloomberg
10:34AM  Sarepta surges after Pfizer gene therapy data raises safety concerns Reuters
10:23AM  Sarepta surges after Pfizer gene therapy data raises safety concerns Reuters
10:18AM  Pfizer gene therapy for rare muscle disease shows promise in small, early study Reuters
Jun-27-19 08:48AM  Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock? Zacks
Jun-24-19 04:14PM  This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data Investor's Business Daily
Jun-18-19 07:08AM  The Sarepta Therapeutics (NASDAQ:SRPT) Share Price Is Up 612% And Shareholders Are Delighted Simply Wall St.
Jun-13-19 10:47AM  Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray American City Business Journals
Jun-10-19 03:44PM  Heres What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT) Insider Monkey
Jun-09-19 07:27AM  Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy? Motley Fool
Jun-07-19 09:30AM  Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue? Zacks
09:24AM  Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
Jun-06-19 06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
Jun-04-19 04:30PM  Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
May-31-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-26-19 03:56AM  Market Weekly Review: Lower Prices Create Buying Opportunities TipRanks
May-14-19 10:38PM  Edited Transcript of SRPT earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
04:27PM  This Biotech Is More Than Its Lead Gene Therapies: Here Are 4 Drugs To Note Investor's Business Daily
May-10-19 01:24AM  Sarepta Therapeutics (SRPT) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 11:05AM  Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up Zacks
10:44AM  When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Simply Wall St.
May-08-19 05:35PM  Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:26PM  Sarepta Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM  Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
02:30PM  Sarepta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
08:30AM  Sarepta Announces Agreement with Nationwide Childrens Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy GlobeNewswire
May-02-19 06:43PM  Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
May-01-19 04:30PM  Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019 GlobeNewswire
Apr-30-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
03:18PM  5 Biotech Stocks for a Long-Lived Portfolio InvestorPlace
Apr-29-19 02:40PM  TripAdvisor CEOs compensation plunged 95 percent in 2018 American City Business Journals
09:11AM  Sarepta CEO's pay dropped 98 percent in 2018 American City Business Journals
08:25AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Apr-26-19 07:57AM  Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More Benzinga
Apr-25-19 10:34AM  Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-23-19 07:20AM  3 Stocks Warren Buffett Would Love Motley Fool
Apr-22-19 05:55AM  Pfizer Stock Suffers From an Underappreciated Drugs Pipeline InvestorPlace
Apr-19-19 11:50AM  Here is What Hedge Funds Think About Sarepta Therapeutics Inc (SRPT) Insider Monkey
Apr-17-19 11:10AM  Wave Life Sciences Plunges After DMD Study Data Readout Zacks
Apr-13-19 09:38AM  The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs Benzinga
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
08:30AM  Sarepta Therapeutics Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference GlobeNewswire
Apr-03-19 06:30AM  Ex-Sarepta execs join new Atlas-backed muscular disease startup fueled by $50M American City Business Journals
Mar-29-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-28-19 04:31PM  How This Biotech Stock Is Reinforcing Its Ironclad Hold On A Key Market Investor's Business Daily
10:20AM  Sarepta plans second Duchenne drug application this year American City Business Journals
09:21AM  Sarepta Therapeutics stock up 3.4% after Phase 3 interim analysis shows positive results for DMD drug MarketWatch
08:30AM  Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study GlobeNewswire
Mar-27-19 01:13PM  8 Genomic Testing Stocks That Can Ease the Sting of Theranos InvestorPlace
Mar-26-19 08:06AM  Is Sarepta Therapeutics a Good Gene Therapy Stock to Buy Now? Motley Fool
Mar-25-19 07:30AM  Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program GlobeNewswire
Mar-15-19 02:55PM  Sarepta Therapeutics' Charts Look Risky
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos -11.12%
04:37PM  Why NIO, Brown-Forman, and Sarepta Therapeutics Slumped Today Motley Fool
03:39PM  Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today InvestorPlace
08:20AM  Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-05-19 07:32PM  Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock GlobeNewswire
04:02PM  Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock GlobeNewswire
Mar-04-19 11:36AM  Why NOW Is the Time to Buy Gene Therapy Stocks InvestorPlace
Mar-01-19 11:14PM  Edited Transcript of SRPT earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahatme SandeshEVP, CFO & CBOAug 15Option Exercise24.739,754241,23230,179Aug 15 04:33 PM
Barry RichardDirectorAug 14Buy122.503,700453,2503,177,065Aug 14 04:38 PM
Barry RichardDirectorAug 12Buy122.501,300159,2503,173,365Aug 13 04:31 PM
INGRAM DOUGLAS SPresident & CEOAug 12Buy123.0716,2522,000,160432,197Aug 12 05:48 PM
Wigzell Hans Lennart RudolfDirectorMay 23Option Exercise7.8010,00078,00021,717May 24 08:03 PM
Wigzell Hans Lennart RudolfDirectorMay 23Sale120.0010,0001,200,00011,717May 24 08:03 PM
Mahatme SandeshEVP, CFO & CBOMar 19Option Exercise21.4615,486332,30819,354Mar 20 08:00 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Option Exercise23.8565,0001,550,25073,649Feb 08 08:02 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Sale145.0065,0009,425,0008,649Feb 08 08:02 PM
Howton David TSVP, General CounselFeb 01Option Exercise21.6521,500465,39149,571Feb 01 08:25 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Option Exercise22.547,500169,03530,266Feb 01 08:27 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Sale140.0015,0002,100,00015,266Feb 01 08:27 PM
Howton David TSVP, General CounselFeb 01Sale140.0030,0004,200,00019,571Feb 01 08:25 PM
Mahatme SandeshEVP, CFO & CBOJan 31Option Exercise23.8521,198505,57229,847Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 31Sale130.7221,1982,771,0038,649Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Option Exercise18.2743,802800,07752,451Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Sale130.0043,8025,694,2608,649Feb 01 08:24 PM
Wigzell Hans Lennart RudolfDirectorNov 01Option Exercise8.946,66759,60316,751Nov 02 06:01 PM
Wigzell Hans Lennart RudolfDirectorNov 01Sale140.506,667936,71410,084Nov 02 06:01 PM
BEHRENS M KATHLEENDirectorOct 31Option Exercise3.9610,00039,600126,534Nov 02 06:00 PM
BEHRENS M KATHLEENDirectorOct 31Sale131.7110,0001,317,100116,534Nov 02 06:00 PM
INGRAM DOUGLAS SPresident & CEOOct 30Buy120.3916,6952,009,872415,945Oct 30 07:05 PM
Mahatme SandeshEVP, CFO & CBOOct 24Option Exercise14.8889,4001,330,389128,185Oct 26 06:43 PM
Mahatme SandeshEVP, CFO & CBOOct 24Sale127.74107,52413,735,11620,661Oct 26 06:43 PM